ClinicalTrials.gg
Status unknownNCT03638726Updated Oct 9, 2018

Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification

A Phase 4 interventional study of Atropine sulfate and epinephrine and Topical cyclopentolate and phenylephrine in Cataract, Mydriasis and Adverse Drug Event, sponsored by Dar El Oyoun Hospital. Status unknown at 1 site in Egypt. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-10-09.

Sponsored by Dar El Oyoun Hospital · Phase 4, Interventional, and Other

The sponsor has not verified this record recently (last verified Oct 2018), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Mydriatic eye drops are routinely used before phacoemulsification but they are not free of drawbacks. Several alternatives were tried to overcome their limitations.

Read the detailed description

The study will include 20 patients with bilateral cataract (40 eyes). The experimental group will include eyes for which a new injectable mydriatic combination are used to dilate the pupil. The control group will include cases where standard mydriatic eye drops are used.

02

Conditions studied

  • Cataract
  • Mydriasis
  • Adverse Drug Event

Keywords

  • intraoperative mydriasis
  • subconjunctival atropine
  • intracameral epinephrine
  • cataract surgery
03

In context

Cataract

1,629 studies on the registry are indexed under Cataract; 235 are open to participants now.

This study's planned enrollment of 40 is below the median of 79 across 1,092 interventional studies indexed under Cataract.

Browse Cataract studies →

Lead sponsor

Dar El Oyoun Hospital is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cases of bilateral visually significant cataract

Exclusion criteria

Exclusion Criteria:

  • Poor pupil dilation(less than 6 mm diameter).
  • History of previous eye surgery or trauma
  • History of use of eye drops affecting pupil size such as pilocarpine.
  • Known drug allergy to cyclopentolate,phenylephrine, atropine sulfate or epinephrine.
  • Pediatric age group (less than 18 years old).
  • Pupil abnormalities, such as anisocoria or neurological disorders.
  • Associated glaucoma, uveitis, corneal, retinal or optic nerve disease.
  • Cases scheduled for phacoemulsification under general anaesthesia (to exclude possible ocular and systemic effects or interactions of anaesthetic agents).
  • Patients with bleeding tendency or on anti-coagulant therapy (because peribulbar and subconjunctival injections are used).
05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Atropine sulfate and Epinephrine

    Perioperative pupil dilation is achieved by combined use of subconjunctival Atropine sulfate 0.6 mg ( parasympathetic antagonist) and intracameral Epinephrine 1:100000 ( sympathetic agonist).

    Drug: Atropine sulfate and epinephrine

  • Other
    Topical cyclopentolate and phenylephrine

    Preoperative pupil dilation was achieved using topical cyclopentolate and phenylephrine.

    Drug: Topical cyclopentolate and phenylephrine

Interventions

  • DrugAtropine sulfate and epinephrine

    Drug pages: Atropine · Epinephrine

    Experimental arm:Combined use of subconjunctival atropine sulfate 0.6 mg ( parasympathetic antagonist) and intracameral epinephrine 1:100000 ( sympathetic agonist). Control arm :topical mydriatics are used for pupil dilation.

    Also known as: Atropine (Misr.co), Epinephrine (Misr.co)

  • DrugTopical cyclopentolate and phenylephrine

    Drug pages: Cyclopentolate · Phenylephrine

    Control arm: Preoperative cyclopentolate and phenylephrine eye drops are used.

    Also known as: Cyclophrine eye drops

06

What researchers measure

Primary outcomes

  1. Intraoperative pupil diameter

    Intraoperative pupil diameter measurements of involved eye in mm

    Time frame: 1 day

Secondary outcomes

  1. Postoperative complications

    Complications such as subconjunctival hemorrhage or corneal edema \[Time Frame: starting from the first postoperative day till one month\]

    Time frame: Starting from first postoperative day till one month.

  2. Postoperative corneal thickness

    Measured by specular microscopy in ( mm )

    Time frame: 1 month after surgery

  3. Postoperative corneal endothelial density

    Measured by specular microscopy in ( cell number/mm2)

    Time frame: 1 month after surgery

  4. Postoperative pupil diameter

    Postoperative diameter of involved eye in mm

    Time frame: one day, one week and one month after surgery

  5. Postoperative visual acuity

    Postoperative best corrected distance visual acuity in logmar units.

    Time frame: One day, one week and one month after surgery

  6. Postoperative intraocular pressure (IOP)

    Postoperative IOP measured in mmHg

    Time frame: One day, one week and one month after surgery

07

Study locations

1 of 1 sites recruiting
  • Dar El Oyoun Hospital
    Cairo, Giza 1261, Egypt
    Recruiting
    • Khaled Samir, MD · Contact
08

References and documents

Individual participant data

Plan to share: Undecided — Identity and names of participant will be hidden. Data related to outcome measures can be shared

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03638726
Lead sponsor
Dar El Oyoun Hospital
Responsible party
Dr. Ashraf Nossair, MD (Associate Professor of Ophthalmology, Cairo University, Dar El Oyoun Hospital) — Principal investigator
First posted
Aug 20, 2018
Start date
Sep 28, 2018
Primary completion
Mar 2019 (estimated)
Completion
Jun 2019 (estimated)
Last update
Oct 9, 2018

Study contacts

Ewais
Contact
waelewais74@gmail.com
+01223638543
Ali
Contact
+01005005707
Nossair
principal investigator · Dar El Oyoun Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atropine · Epinephrine

Start the discussion